Appareil pulmonaire LUMINOSITY (M14-239) Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Sein métastatique triple négatif CLAG525B2101 A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer. Paris JEAN-YVES PIERGA
Appareil pulmonaire MELROSE Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiological progression : the MELROSE trial Paris
Appareil pulmonaire IMMUNO ADDICT (GFPC 06-2018) A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018) Paris CATHERINE DANIEL
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Appareil pulmonaire NIVOTHYM (EORTC-1525) Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Paris NICOLAS GIRARD
Appareil pulmonaire SAVANNAH (D5084C00007) Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in;Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally;Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed;Following Treatment with Osimertinib (The SAVANNAH Study) Paris NICOLAS GIRARD
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Appareil pulmonaire SKYSCRAPER-06 (BO42592) A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer. Paris
Appareil pulmonaire HERTHENA-Lung01 U31402-A-U201 HERTHENA-Lung01: A Phase 2 Randomized Open-Label;Study of Patritumab Deruxtecan (U3-1402) in Subjects with;Previously Treated Metastatic or Locally Advanced EGFRmutated;Non-Small Cell Lung Cancer (NSCLC) Paris NICOLAS GIRARD